Tenaya Therapeutics, Inc. (TNYA) has disclosed a new risk, in the Debt & Financing category.
Tenaya Therapeutics, Inc. faces significant financial challenges as it navigates the costly and time-intensive process of pharmaceutical development. With $104.6 million in cash reserves as of year-end 2023, the company may yet seek additional funds, potentially diluting current shareholders or imposing restrictive covenants. The pursuit of necessary capital could also result in relinquishing rights to valuable intellectual property or product candidates, which could compromise Tenaya’s business strategy and operational flexibility. Failure to secure funding on suitable terms could force a scale-back or cessation of certain projects, adversely affecting the company’s future prospects.
The average TNYA stock price target is $14.67, implying 223.84% upside potential.
To learn more about Tenaya Therapeutics, Inc.’s risk factors, click here.
